Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;19(1):10-5.
doi: 10.1016/j.cardfail.2012.11.006.

Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort

Affiliations

Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort

Carrie A Geisberg et al. J Card Fail. 2013 Jan.

Abstract

Background: Breast cancer (BC) treatments can cause heart failure (HF) in a subset of patients. ACC/AHA guidelines classify patients receiving cardiotoxic medications as stage A, a high-risk population for the development of HF. Circulating neuregulin (NRG) correlates with outcomes in stage C and D HF. We examined the levels of NRG in a BC cohort receiving cardiotoxic chemotherapy and its relationship with adverse cardiac effects during the transition from stage A to stage B or C HF.

Methods and results: In an ongoing prospective study, a planned interim analysis of 78 BC women receiving either anthracycline (AC) or trastuzumab (Tsz) was performed. Biometric data, cardiac risk factors, and NRG levels, were collected before chemotherapy and after completion of AC therapy and/or 3 months into Tsz therapy. Cardiac function was measured by left ventricular ejection fraction (LVEF) by echocardiography at the above time points and longitudinally as standard of care. The interim cohort was predominately white with stage II BC and a median age of 50 years. A reduction of >10 absolute percentage points in LVEF was observed in 21.4% of the cohort, representing a transition from stage A to stage B or C HF. A statistically significant drop in plasma NRG was observed in women treated with AC and/or Tsz (P < .001). Additionally, baseline NRG correlated with the maximal change in LVEF.

Conclusions: More than 20% of women experienced cardiac dysfunction, detected by decline in LVEF, and were reclassified as stage B or C HF. Plasma NRG levels were reduced after exposure to cardiotoxic chemotherapy, suggesting a loss in a cardioprotective growth factor. Higher baseline NRG levels were observed in those with the greatest decline in LVEF, supporting the continued investigation of NRG as a potential prognostic marker in early-stage HF.

PubMed Disclaimer

Conflict of interest statement

Disclosures:

The authors have no potential conflicts or relevant financial disclosures related to this study.

Figures

Figure 1
Figure 1. Cardiac Risk Factors in Treated BC Patients
Women treated for breast cancer (BC) have significant cardiac risk factors. A personal history of hypertension was reported in 58%, 24% had hyperlipidemia (HL), 10% had diabetes (DM), 1% had coronary artery disease (CAD), 30% had former or ongoing tobacco use, 23% had a family history of heart failure (family Hx HF), 68% were overweight (BMI > 25), and 63% reported low levels of physical activity.
Figure 2
Figure 2. Change in Cardiac Function During Follow-up
Absolute maximum change in left ventricular ejection fraction (LVEF) from baseline in 70 individuals who were treated with either anthracycline chemotherapy or trastuzumab for breast cancer (BC). Seven patients had no change in LVEF from baseline and are represented without bars. Fifteen women (24.1%) experienced a reduction in LVEF of greater than 10 units during the follow-up period as defined by the dotted line.
Figure 3
Figure 3. Change in Plasma NRG Due to Chemotherapy
AC and/or Tsz therapy caused a statistically significant drop in circulating levels of plasma neuregulin (NRG), a cardiac growth factor (baseline NRG median 4.0 ng/ml, Post Chemo NRG median 2.9 ng/ml, n = 62, p = < 0.001).

References

    1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–235. Epub 2005/09/15. - PubMed
    1. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2002;13(6):819–29. Epub 2002/07/19. - PubMed
    1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90. Epub 2009/04/11. - PubMed
    1. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation. 2009;120(4):310–7. Epub 2009/07/15. - PMC - PubMed
    1. Geisberg CA, Wang G, Safa RN, Smith HM, Anderson B, Peng X-Y, et al. Circulating neuregulin-1 beta levels vary according to the angiographic severity of coronary artery disease and ischemia. Coronary artery disease. 2011;22(8):577–82. - PMC - PubMed

Publication types

MeSH terms